Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
A Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
Sponsor: AMAG Pharmaceuticals, Inc.
Listed as NCT04268849, this PHASE3 trial focuses on Iron Deficiency Anemia and remains actively recruiting participants. Sponsored by AMAG Pharmaceuticals, Inc., it has been updated 10 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE3
Status: Unknown → Recruiting
-
Jul 2025 — Nov 2025 [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Mar 2022 — Jul 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AMAG Pharmaceuticals, Inc.
- Auerbach Hematology Oncology Associates P C
For direct contact, visit the study record on ClinicalTrials.gov .